申请人:Puskas Laszlo
公开号:US20130131096A1
公开(公告)日:2013-05-23
The invention relates to compounds of the general formula (I) and their pharmaceutically acceptable salts (in which formula R
1
represents a hydrogen atom, lower alkyl group, lower alkenyl group, lower cycloalkyl group, aryl group, aralkyl group or heterocyclic group, wherein, the above groups are optionally substituted in ortho, meta and/or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; R
2
represents a hydrogen atom, lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted with one or more halogen atoms; R
3
represents a lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted in ortho, meta or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; R
4
represents a hydrogen atom, lower alkyl group or any acidic functional group;
n is 1 or 2).
The compounds according to the invention can be used in the medicine mainly for the treatment of diseases associated with neurological and/or oxidative stress.
本发明涉及一般式(I)的化合物及其药学上可接受的盐(其中R1表示氢原子,低碳基,低烯基,低环烷基,芳基,芳基烷基或杂环基,其中上述基团在邻位,间位和/或对位上可以选择性地被1、2、3或4个电子提取基团或电子捐赠基团取代;R2表示氢原子,低碳基,芳基,芳基烷基或杂环基,其中上述基团可以选择性地被一个或多个卤素原子取代;R3表示低碳基,芳基,芳基烷基或杂环基,其中上述基团在邻位,间位或对位上可以选择性地被1、2、3或4个电子提取基团或电子捐赠基团取代;R4表示氢原子,低碳基或任何酸性官能团;n为1或2)。根据本发明的化合物主要可用于治疗与神经学和/或氧化应激相关的疾病。